Differential levels of soluble endoglin (CD105) in myeloid malignancies - PubMed (original) (raw)
Differential levels of soluble endoglin (CD105) in myeloid malignancies
Luana Calabrò et al. J Cell Physiol. 2003 Feb.
Abstract
Angiogenesis contributes to disease progression in solid and hematopoietic malignancies, and endoglin (CD105), a component of the transforming growth factor (TGF)-beta receptor complex, is a powerful marker of neovascularization. Elevated amounts of soluble CD105 (sCD105) have been recently identified in selected solid tumors but no data are available on sCD105 in hematopoietic malignancies. Therefore, levels of sCD105 were investigated in sera of patients with acute myeloid leukemia (AML) (n = 10) or chronic myeloproliferative disorders (CMD) (n = 28), and correlated with those of soluble TGF-beta(1) (sTGF-beta(1)). Dot blot assay detected higher amounts of sCD105 (P < 0.05) both in AML (4.34 +/- 2.62 OD/mm(2)) and in CMD (3.71 +/- 2.09 OD/mm(2)) patients than in healthy subjects (n = 14, 2.38 +/- 1.18 OD/mm(2)). Instead, enzyme-linked immunosorbent assay (ELISA) identified (P < 0.05) lower and higher levels of sTGF-beta(1) in AML (32,017 +/- 1,900 pg/ml) and CMD (60,700 +/- 19,200 pg/ml) patients, respectively, compared to healthy individuals (n = 11, 47,173 +/- 5,443 pg/ml). In essential thrombocythemia (ET) patients with thrombotic episodes, levels of sCD105 were lower (P < 0.05) compared to patients without thrombotic complications, and inversely correlated with those of sTGF-beta(1) (r = 0.94). Conversely, amounts of sCD105 directly correlated with levels of sTGF-beta(1) (r = 0.74) in ET patients without thrombotic events. Our results show that high levels of sCD105 are present in myeloid malignancies that are characterized by a high cellular proliferation rate, and suggest that an altered balance between sCD105 and sTGF-beta(1) might favor disease progression and clinical complications.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
- Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma.
Tsirakis G, Pappa CA, Spanoudakis M, Chochlakis D, Alegakis A, Psarakis FE, Stratinaki M, Stathopoulos EN, Alexandrakis MG. Tsirakis G, et al. Eur J Intern Med. 2012 Jun;23(4):368-73. doi: 10.1016/j.ejim.2012.01.012. Epub 2012 Mar 3. Eur J Intern Med. 2012. PMID: 22560388 - Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications.
Musolino C, Alonci A, Bellomo G, Loteta B, Quartarone E, Gangemi D, Massara E, Calabrò L. Musolino C, et al. Eur J Haematol. 2004 Jun;72(6):416-9. doi: 10.1111/j.1600-0609.2004.00253.x. Eur J Haematol. 2004. PMID: 15128420 - Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Pappa CA, Alexandrakis MG, Boula A, Psarakis FE, Kolovou A, Bantouna V, Stavroulaki E, Tsirakis G. Pappa CA, et al. Hematol Oncol. 2013 Dec;31(4):201-5. doi: 10.1002/hon.2044. Epub 2013 Apr 11. Hematol Oncol. 2013. PMID: 23576184 - Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M. Fonsatti E, et al. J Cell Physiol. 2001 Jul;188(1):1-7. doi: 10.1002/jcp.1095. J Cell Physiol. 2001. PMID: 11382917 Review. - Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.
Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Fonsatti E, et al. Curr Cancer Drug Targets. 2003 Dec;3(6):427-32. doi: 10.2174/1568009033481741. Curr Cancer Drug Targets. 2003. PMID: 14683500 Review.
Cited by
- Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T. Olsen OE, et al. Blood Cancer J. 2014 Mar 21;4(3):e196. doi: 10.1038/bcj.2014.16. Blood Cancer J. 2014. PMID: 24658374 Free PMC article. - Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure.
Coral-Alvarado PX, Garces MF, Caminos JE, Iglesias-Gamarra A, Restrepo JF, Quintana G. Coral-Alvarado PX, et al. Int J Rheumatol. 2010;2010:969383. doi: 10.1155/2010/969383. Epub 2010 Aug 24. Int J Rheumatol. 2010. PMID: 20871866 Free PMC article. - Genome Wide Expression Profiling of Cancer Cell Lines Cultured in Microgravity Reveals Significant Dysregulation of Cell Cycle and MicroRNA Gene Networks.
Vidyasekar P, Shyamsunder P, Arun R, Santhakumar R, Kapadia NK, Kumar R, Verma RS. Vidyasekar P, et al. PLoS One. 2015 Aug 21;10(8):e0135958. doi: 10.1371/journal.pone.0135958. eCollection 2015. PLoS One. 2015. PMID: 26295583 Free PMC article. - Endoglin in the Spotlight to Treat Cancer.
González Muñoz T, Amaral AT, Puerto-Camacho P, Peinado H, de Álava E. González Muñoz T, et al. Int J Mol Sci. 2021 Mar 20;22(6):3186. doi: 10.3390/ijms22063186. Int J Mol Sci. 2021. PMID: 33804796 Free PMC article. Review. - Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?
Otten J, Bokemeyer C, Fiedler W. Otten J, et al. J Oncol. 2010;2010:317068. doi: 10.1155/2010/317068. Epub 2010 May 13. J Oncol. 2010. PMID: 20490264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous